

Financial news for SUPN dated on 2020-05-12: Supernus Pharma Files For Non-Timely 10Q

Financial news for SUPN dated on 2020-04-28: Supernus To Purchase CNS Portfolio From US WorldMeds For \$300M In Upfront Cash Payment Plus Cash Milestone Payments Up To \$230M

Financial news for SUPN dated on 2020-04-21: Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138; Navitor To Receive \$25M Upfront Payment and Potential \$410M-\$475M In Milestones

Financial news for SUPN dated on 2020-04-16: Stifel Maintains Hold on Supernus Pharmaceuticals, Lowers Price Target to \$24

Financial news for SUPN dated on 2020-02-25: Supernus Announces Phase III P302 Trial Of SPN-810 For Treatment Of IA In ADHD Patients 6 To 11 Years Old Did Not Meet Primary Endpoint

Financial news for SUPN dated on 2020-02-25: Supernus Sees FY20 Operating Earnings \$70M-\$100M, Net Product Sales \$360M-\$390M

Financial news for SUPN dated on 2019-12-09: Supernus Pharma Shares To Resume Trade At 4:45 p.m. EST

Financial news for SUPN dated on 2019-12-09: UPDATE: Results Showed Median Percent Reduction of 58.6% In The Average Weekly Frequency Of Impulsive Aggression

Financial news for SUPN dated on 2019-12-09: Supernus Pharmaceuticals Provides Results From Its Phase 3 Study Of SPN-9810 For The Treatment Of Impulsive Aggression In ADHD Patients

Financial news for SUPN dated on 2019-12-09: Supernus Pharma Offers Update On Results From Phase 3 Study Of SPN-810 For Treatment Of Impulsive Aggression In ADHD Patients: Baseline Was Not Statistically Significant Vs. Placebo

Financial news for SUPN dated on 2019-12-09: Supernus Pharma Shares Halted News Pending

Financial news for SUPN dated on 2019-11-11: Supernus Pharma Reports Submission Of New Drug Application for SPN-812 For Treatment Of ADHD

Financial news for SUPN dated on 2019-11-07: Stifel Nicolaus Downgrades Supernus Pharmaceuticals to Hold, Lowers Price Target to \$23

Financial news for SUPN dated on 2019-11-06: Jefferies Downgrades Supernus Pharmaceuticals to Hold

Financial news for SUPN dated on 2019-11-05: Supernus Pharma Shares Resume Trade, Down 24.5%

Financial news for SUPN dated on 2019-11-05: Supernus Pharma Shares To Resume Trade At 5:25 p.m. EST

Financial news for SUPN dated on 2019-11-05: Supernus Pharmaceuticals Q3 EPS \$0.54 Misses \$0.6 Estimate, Sales \$102.14M Miss \$109.54M Estimate

Financial news for SUPN dated on 2019-11-05: Supernus Pharma Reports Phase 3 P301 Trial Of SPN-810 For Treatment Of IA In ADHD Patients 6-11 Did Not Meet Primary Endpoint

Financial news for SUPN dated on 2019-11-05: Supernus Shares Halted News Pending

Financial news for SUPN dated on 2019-08-06: Supernus Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 sales results. The company also cut FY19 net product sales guidance.

Financial news for SUPN dated on 2019-08-06: Supernus Pharmaceuticals Cuts FY19 Net Product Sales Guidance From \$435M-\$455M To \$400M To \$410M

Financial news for SUPN dated on 2019-08-06: Supernus Pharmaceuticals Q2 EPS \$0.61 Beats \$0.57 Estimate, Sales \$104.695M Miss \$108.67M Estimate

Financial news for SUPN dated on 2019-06-17: 'Goldman Sachs is sounding the alarm to clients that technology stocks are overvalued' -Earlier CNBC Article

Financial news for SUPN dated on 2019-05-07: Supernus Pharmaceuticals Q1 EPS \$0.34 Misses \$0.47 Estimate, Sales \$85.474M Miss \$103.87M Estimate

Financial news for SUPN dated on 2019-03-28: Supernus Announces P304 Phase III Data Confirming 'Positive' Results From Previous Three Phase III Studies On SPN-812 In

ADHD; Reached Statistical Significance Compared To Placebo In Primary Endpoint

Financial news for SUPN dated on 2019-02-26: Supernus Pharmaceuticals Q4 EPS \$0.48 Beats \$0.27 Estimate, Sales \$115.934M Beat \$105.4M Estimate

Financial news for SUPN dated on 2018-12-20: Supernus Shares Resume Trade, Not Yet Seeing Updated Last Price

Financial news for SUPN dated on 2018-12-20: Supernus Reports Phase III Study For SPN-812 In Adolescents With ADHD Met Primary Endpoint

Financial news for SUPN dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for SUPN dated on 2018-12-14: Supernus Pharma Reports FDA Approved Of sNDA To Expand Oxtellar XR Label To Include Monotherapy

Financial news for SUPN dated on 2018-12-06: Supernus Pharma Shares Resume Trade, Down 10%

Financial news for SUPN dated on 2018-12-06: Supernus Pharma Shares To Resume Trade At 9 a.m. EST

Financial news for SUPN dated on 2018-12-06: Supernus Reports Results From 2 Phase III Studies For SPN-812 In Children With ADHD: P301, P303 Met Primary Endpoint

Financial news for SUPN dated on 2018-12-06: Supernus Shares Halted News Pending

Financial news for SUPN dated on 2018-11-12: B. Riley FBR Maintains Buy on Supernus Pharmaceuticals, Lowers Price Target to \$65

Financial news for SUPN dated on 2018-11-06: Supernus Pharmaceuticals, Inc. Sees Narrows FY18 Sales Guidance From \$385M-\$400M To \$388M-\$395M vs \$398.7M Est.

Financial news for SUPN dated on 2018-11-06: Supernus Pharmaceuticals, Inc. Q3 EPS \$0.52 Beats \$0.39 Estimate, Sales \$102.996M Beat \$101.84M Estimate

Financial news for SUPN dated on 2018-10-29: Mizuho On Supernus Pharma: Buy Stock Into ADHD Data Catalyst; Reiterates Buy, \$61 Price Target

Financial news for SUPN dated on 2018-09-18: Mizuho Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces \$61 Price Target

Financial news for SUPN dated on 2018-09-13: Supernus Raises FY18 Research & Development Expenses Guidance From \$80M To \$95M

Financial news for SUPN dated on 2018-09-13: Supernus Raises Narrows FY18 Net Product Sales Guidance From \$375M-\$400M To \$385M-\$400M vs \$401.54M Est.

Financial news for SUPN dated on 2018-09-13: Supernus To Acquire Biscayne Neurotherapeutics ; Transaction Provides Upfront Payment Of \$15M, Additional Payments Include \$73M Contingent On Development Milestones And \$95M Contingent On Sales Milestones

Financial news for SUPN dated on 2018-09-06: Supernus Reports Winning Of Appeal Related To Oxtellar XR Against TWI

Financial news for SUPN dated on 2018-09-04: Supernus Pharma 8-K Shows Enrollment In Phase 3 Studies For SPN-812 Ahead Of Schedule, Complete In P301, P302, P303 Studies, Data Expected In Q4'18

Financial news for SUPN dated on 2018-08-07: Supernus Pharma Narrows FY18 Guidance: Net Product Sales From \$375M-\$400M To \$385M-\$400M vs \$403.9M Estimate, Raises Operating Earnings From \$125M-\$135M To \$130M-\$140M

Financial news for SUPN dated on 2018-08-07: Supernus Pharmaceuticals Q2 EPS \$0.57 Beats \$0.43 Estimate, Sales \$99.5M Miss \$99.86M Estimate

Financial news for SUPN dated on 2018-05-08: Supernus Pharmaceuticals Sees FY2018 Sales \$375.0M-400.0M vs \$398.50M Est

Financial news for SUPN dated on 2018-05-08: Supernus Pharmaceuticals Q1 EPS \$0.49 Beats \$0.33 Estimate, Sales \$90.429M Beat \$85.29M Estimate

Financial news for SUPN dated on 2018-02-27: Supernus Reports Q4 EPS \$0.26 vs \$0.27 Est., Sales \$88.44M vs \$87.28M Est.

Financial news for SUPN dated on 2018-02-08: Supernus Pharma Shares Now Up 3% For Session, Over \$39 Level; BZ NOTE: Name Has Not Previously Been Mentioned By The Rumor

Mill

Financial news for SUPN dated on 2018-02-08: Supernus Shares Up Almost \$1 Over Last Few Mins. As Traders Circulating Chatter Co. Received Takeover Bid

Financial news for SUPN dated on 2018-02-01: Berenberg Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces \$66.00 Price Target

Financial news for SUPN dated on 2018-01-02: Several Biotechs Higher Tuesday Amid Jefferies Mention Of Price Increases In Effect; Insys +13.21%, Synergy Pharmaceuticals +6.72%, Allergan +3.22%, Horizon Pharma +0.99%, Supernus Pharma +0.25%, Teva Pharma +0.53%; Collegium An Outlier, Down 0.64%

Financial news for SUPN dated on 2017-12-04: Janney Capital Upgrades Supernus Pharmaceuticals to Buy

Financial news for SUPN dated on 2017-11-08: Stifel Nicolaus Upgrades Supernus Pharmaceuticals to Buy

Financial news for SUPN dated on 2017-11-07: Suntrust Out Defending Supernus, Says They Would Take Advantage Of Weakness As Potential In Trokendi XR With 40 New Sales Reps Added

Financial news for SUPN dated on 2017-11-07: Supernus Shares Down 13.5% Tues. Morning Despite Q3 Earnings Beat, Raised Guidance Mon. Afternoon; Cantor Analyst Said Stock's 'weak recent performance may be attributable to confusion regarding interim look at SPN-810 pivotal program and discontinuation'

Financial news for SUPN dated on 2017-11-06: Supernus Pharmaceuticals FY17 Sales Outlook Raised From \$280M-\$290M to \$290M-\$295M vs \$295.89M Est.

Financial news for SUPN dated on 2017-11-06: Supernus Pharmaceuticals Reports Q3 EPS \$0.29 vs \$0.27 Est., Sales \$80.398M vs \$77.6M Est.

Financial news for SUPN dated on 2017-10-19: FBR Capital Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces \$53.00 Price Target

Financial news for SUPN dated on 2017-09-19: Stifel Nicolaus Downgrades Supernus Pharmaceuticals to Hold

Financial news for SUPN dated on 2017-09-18: Supernus Pharmaceuticals Shares Resume Trading, Down 4.13%

Financial news for SUPN dated on 2017-09-18: Supernus Pharma Shares To Resume Trade At 4:30 p.m. EDT

Financial news for SUPN dated on 2017-09-18: Supernus Announces Interim Results From Phase III Trial Of SPN-810, Will Eliminate 18mg Dosing Arm, Will Randomize Patients To Increase Probability Of Reaching Statistically Significant Outcome

Financial news for SUPN dated on 2017-09-18: Supernus Pharmaceuticals Shares Halted, News Pending

Financial news for SUPN dated on 2017-08-15: Supernus Announces US District Court Ruled TWI Pharma Infringed On Its Patent

Financial news for SUPN dated on 2017-08-02: Supernus Pharma Reports Q2 EPS \$0.32 vs \$0.24 Est., Sales \$75.829M vs \$67.8M Est.

Financial news for SUPN dated on 2017-07-17: PiperJaffray Downgrades Supernus Pharmaceuticals to Neutral

Financial news for SUPN dated on 2017-07-14: Janney Capital Initiates Coverage On Supernus Pharmaceuticals with Neutral Rating, Announces \$47.00 Price Target

Financial news for SUPN dated on 2017-06-21: Supernus Pharma Reports Partner Shire Received FDA Approval For Mydayis For ADHD

Financial news for SUPN dated on 2017-06-01: PiperJaffray Upgrades Supernus Pharmaceuticals to Overweight, Raises Price Target to \$44.00

Financial news for SUPN dated on 2017-05-09: Supernus Sees FY17 Sales \$265-\$275M vs \$275M Est.

Financial news for SUPN dated on 2017-05-09: Supernus Reports Q1 EPS \$0.19 vs \$0.23 Est., Sales \$56.4M vs \$59.3M Est.

Financial news for SUPN dated on 2017-03-07: Supernus Reports Settlement with Actavis on Trokendi XR Patent Litigation

Financial news for SUPN dated on 2017-03-06: Supernus Announces Settlement With Zydus On Patent Litigation, Agrees To Permit Zydus To Sell Generic Version Of Trokendi on Jan. 1, 2023 Or Earlier Under Certain Circumstances

Financial news for SUPN dated on 2017-02-08: Supernus Reports Issuance of Eighth U.S. Patent Protecting Trokendi XR

Financial news for SUPN dated on 2017-01-30: Supernus Reports Issuance of Seventh U.S. Patent Protecting Trokendi XR, Provides Protection Until 2027

Financial news for SUPN dated on 2017-01-23: Supernus Files Form 10-Q for Third Quarter 2016, Is Now Current with All Financial Filings

Financial news for SUPN dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On Supernus Pharmaceuticals at Overweight, Announces \$32.00 Target

Financial news for SUPN dated on 2016-12-12: Supernus Reports Winning of Appeal Case on Oxtellar XR

Financial news for SUPN dated on 2016-07-18: Northland Securities Downgrades Supernus Pharmaceuticals to Market Perform

Financial news for SUPN dated on 2016-07-18: Piper Jaffray Downgrades Supernus Pharmaceuticals to Neutral

Financial news for SUPN dated on 2016-02-08: Jefferies Upgrades Supernus Pharmaceuticals to Buy, Maintains \$18.00 PT

Financial news for SUPN dated on 2016-02-08: Jefferies Upgrades Supernus Pharmaceuticals to Buy, Maintains \$18.00 PT

Financial news for SUPN dated on 2015-10-28: Northland Securities Initiates Coverage on Supernus Pharmaceuticals at Outperform, Announces \$26.00 PT

Financial news for SUPN dated on 2015-10-22: Supernus Announces FDA Acceptance of sNDA to Add Migraine to Trokendi XR Label

Financial news for SUPN dated on 2015-06-18: Jefferies Upgrades Supernus Pharmaceuticals to Buy, Raises PT to \$18.00

Financial news for SUPN dated on 2015-06-12: SunTrust Robinson Humphrey Initiates Coverage on Supernus Pharmaceuticals at Buy

Financial news for SUPN dated on 2014-11-11: SUPernus Pharmaceuticals, Inc. Reports Q3 EPS of \$0.39 vs \$0.36 Est; Revenue of \$52.50M vs \$43.08M Est

Financial news for SUPN dated on 2014-09-04: Supernus Announces Fourth US Patent Protecting Oxtellar XR

Financial news for SUPN dated on 2014-08-11: Supernus Pharmaceuticals, Inc. Sees FY2014 Sales \$105.0M vs \$80.10M Est

Financial news for SUPN dated on 2014-08-11: SUPernus Pharmaceuticals, Inc. Reports Q2 EPS of \$0.08 vs \$(0.16) Est; Revenue of \$27.60M vs \$19.85M Est

Financial news for SUPN dated on 2014-05-12: SUPernus Pharmaceuticals, Inc. Reports Q1 EPS of \$(0.38) vs \$(0.41) Est; Revenue of \$9.08M vs \$9.94M Est

Financial news for SUPN dated on 2014-04-21: Jefferies Initiates Coverage on Supernus Pharmaceuticals, Inc. at Hold, Announces \$9.00 PT

Financial news for SUPN dated on 2014-03-14: Stifel Nicolaus Maintains Buy on Supernus Pharmaceuticals, Inc., Raises PT to \$14.00

Financial news for SUPN dated on 2014-03-12: SUPernus Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.65) Which May Not Compare \$(0.55) Est; Revenue of \$10.30M Which May Not Compare \$7.78M Est

Financial news for SUPN dated on 2013-11-12: SUPernus Pharmaceuticals, Inc. Reports Q3 EPS of \$(0.78) vs \$(0.67) Est; Revenue of \$1.26M vs \$2.54M Est

Financial news for SUPN dated on 2013-08-13: SUPernus Pharmaceuticals, Inc. Reports Q2 EPS of \$(0.89) vs \$(0.65) Est

Financial news for SUPN dated on 2013-05-14: Piper Jaffray Maintains Overweight on Supernus Pharmaceuticals, Inc., Lowers PT to \$13.00

Financial news for SUPN dated on 2013-05-13: SUPernus Pharmaceuticals, Inc. Reports

Q1 EPS of \$(0.60) vs \$(0.71) Est

Financial news for SUPN dated on 2013-03-15: Piper Jaffray Maintains Overweight on Supernus Pharmaceuticals, Inc., Lowers PT to \$14.00

Financial news for SUPN dated on 2013-03-14: SUPernus Pharmaceuticals, Inc. Reports Q4 EPS of \$(0.51) vs \$(0.71) Est; Revenue of \$109.0K vs \$60.0K Est

Financial news for SUPN dated on 2013-03-05: Jefferies Initiates Coverage on Supernus Pharmaceuticals, Inc. at Buy, Announces \$13.00 PT

Financial news for SUPN dated on 2012-12-05: From Earlier: Lazard Capital Markets Initiates Coverage on Supernus Pharmaceuticals, Inc. at Buy, Announces \$6.00 PT

Financial news for SUPN dated on 2012-11-27: Citigroup Initiates Coverage Supernus Pharmaceuticals at Neutral , Announces PT of \$14.00

Financial news for SUPN dated on 2012-11-20: Supernus Pharmaceuticals Reports Positive Phase IIb Results on SPN-810 for Treatment of Impulsive Aggression in ADHD Patients

Financial news for SUPN dated on 2012-11-05: Supernus Awarded Patents Covering Trokendi XR

Financial news for SUPN dated on 2012-08-13: Piper Jaffray Maintains Supernus Pharmaceuticals at Overweight, Raises PT from \$12 to \$15

Financial news for SUPN dated on 2012-06-29: Citigroup Initiates Coverage On Supernus Pharmaceuticals at Neutral, Announces PT of \$6